Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis

American Heart Journal

Volumn 156, Issue 2, 2008, Pages 336-341

  Setoguchi, Soko ^a   Schneeweiss, Sebastian ^a   Avorn, Jerry ^a   Katz, Jeffrey N ^b   Weinblatt, Michael E ^b   Levin, Raisa ^a   Solomon, Daniel H ^a,b  

^a Divisions of Pharmacoepidemiology and Pharmacoeconomics ^*

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; HEALTH HAZARD; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS;

AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; METHOTREXATE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47849128962     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.02.025     Document Type: Article

References (20)

1. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
2. Katz S.D., Rao R., Berman J.W., et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 90 (1994) 12-16
3. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
4. Torre-Amione G., Kapadia S., Benedict C., et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
5. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
6. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
7. MedWatch (U.S. Food and Drug Administration). Remicade (infliximab)-clinical alert: congestive heart failure (2001)
8. Nicola P.J., Maradit-Kremers H., Roger V.L., et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 52 (2005) 412-420
9. Wolfe F., and Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116 (2004) 305-311
10. Nicola P.J., Crowson C.S., Maradit-Kremers H., et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 54 (2006) 60-67
11. Bernatsky S., Hudson M., and Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 44 (2005) 677-680
12. McKenzie D.A., Semradek J., McFarland B.H., et al. The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 53 (2000) 1248-1257
13. Levy A.R., O'Brien B.J., Sellors C., et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10 (2003) 67-71
14. Birman-Deych E., Waterman A.D., Yan Y., et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 43 (2005) 480-485
15. Setoguchi S., Stevenson L.W., and Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 154 (2007) 260-266
16. Lee D.S., Donovan L., Austin P.C., et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 43 (2005) 182-188
17. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 8 Pt 2 (1997) 757-763
18. Ray W.A. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158 (2003) 915-920
19. Cole J., Busti A., and Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 27 (2007) 369-373
20. Giles J.T., Fernandes V., Lima J.A., et al. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Ther 7 (2005) 195-207